Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 14;14:435–444. doi: 10.2147/OTT.S287722

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Han et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The correlation between HSDL2 expression and prognosis of PC patients. (A) Forest plots showed the results of univariate and multivariable logistic regression analysis. (B) The implication of HSDL2 in survival of patients with PC in different expression level of HSDL2 was determined in The Human Protein Atlas. (C) Overall survival rates of PC patients in different expression level of HSDL2 analyzed by Kaplan–Meier. (D and E) Overall survival rates of PC patients with good differentiation and moderate differentiation in relation to HSDL2 expression. (F and G) Overall survival rates of PC patients with early stage and late stage in relation to HSDL2 expression. (H and I) Overall survival rates of PC patients with LN metastasis (-) and LN metastasis (+) in relation to HSDL2 expression.